Granted Patent
B2
US 12,275,802 · App. 17/583,117 · Granted Apr 15, 2025
Compositions and methods for immunotherapy
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER
C07K16/40A61K39/4611A61K39/4621A61K39/4631A61K39/4636A61K39/46431A61K39/46434A61K39/464412A61K39/464495C07K14/7051C07K14/70514C07K14/70517C12N5/0636C12N5/0638A61K2239/22A61K2239/26A61K2239/31A61K2239/38C07K2317/622C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
Claims (21)
1. A method of treating a tumor in a subject, comprising administering to the subject a T cell, wherein the T cell comprises:
a) a chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain comprising a single chain variable fragment (scFv) that binds to a first antigen that is expressed at the surface of a cell of the tumor, and an intracellular signaling domain that is capable of activating the immunoresponsive cell and comprises a signaling domain of CD28, and
b) an inhibitory chimeric antigen receptor (iCAR) comprising an extracellular antigen-binding domain comprising a single chain variable fragment (scFv) that binds to a second antigen that is not expressed on the tumor cell surface, and a signaling domain of an immunoinhibitory receptor selected from the group consisting of CTLA-4, PD-1, LAG-3, 2B4, and BTLA;
wherein binding of the CAR to the first antigen induces cytotoxicity of the T cell, and binding of the iCAR to the second antigen reduces the cytotoxicity of the T cell induced by the CAR.
2. The method of claim 1 , wherein the CAR is recombinantly expressed and/or expressed from a vector.
3. The method of claim 1 , wherein the iCAR is recombinantly expressed and/or expressed from a vector.
4. The method of claim 1 , wherein the T cell is selected from the group consisting of effector T cells, and memory T cells.
5. The method of claim 4 , wherein the effector T cells are selected from the group consisting of helper T cells (CD4+ T cells), and cytotoxic T cells (CD8+ T cells).
6. The method of claim 1 , wherein the T cell is autologous or allogeneic.
7. The method of claim 1 , wherein the first antigen is selected from the group consisting of CD19, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD123, CD133, CD138, CAIX, CEA, CD5, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, Fetal acetylcholine receptor, folate receptor-α, GD2, GD3, HER-2, IL-13R-α2, κ-light chain, LeY, L1 cell adhesion molecule, Mesothelin, Muc-1, Muc-16, oncofetal antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, and VEGF-R2.
8. The method of claim 7 , wherein the first antigen is selected from the group consisting of CD19, PSMA, mesothelin, and CD56.
9. The method of claim 1 , wherein the iCAR further comprises a transmembrane domain selected from the group consisting of a CD4 polypeptide, a CD8 polypeptide, a CTLA-4 polypeptide, a PD-l polypeptide, a LAG-3 polypeptide, a 2B4 polypeptide, and a BTLA polypeptide.
10. The method of claim 1 , wherein the second antigen is selected from the group consisting of an Epithelial-mesenchymal transition (EMT) antigen, cytokeratin, human leukocyte antigens (HLAs), Opioid-binding protein/cell adhesion molecule (OPCML), HYAL2, Deleted in Colorectal Carcinoma (DCC), Scaffold/Matrix attachment region-binding protein 1 (SMAR1), CD33, CD38, and E-cadherin.
11. The method of claim 1 , wherein the method reduces the burden of the tumor.
12. The method of claim 1 , wherein the method reduces the number of the tumor cells.
13. The method of claim 1 , wherein the method reduces the size of the tumor.
14. The method of claim 1 , wherein the method eradicates the tumor in the subject.
15. The method of claim 1 , wherein the tumor is cancer.
16. The method of claim 1 , wherein the tumor is a solid tumor.
17. The method of claim 1 , wherein the tumor is a hematological tumor.
18. The method of claim 1 , wherein the tumor is selected from the group consisting of blood cancer, B cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, ovarian cancer, prostate cancer, pancreatic cancer, lung cancer, breast cancer, sarcoma, and acute myeloid leukemia (AML).
Continuity (4)
Continuation
PCTUS2014030671
· Mar 17, 2014
Provisional Application
61802118
· Mar 15, 2013
References Cited (117)
US 5712149A
· Roberts
· 1998
[cited by applicant]
JP 2016507499A
· 2016
[cited by applicant]
JP 2016508728A
· 2016
[cited by applicant]
WO WO2008038587A1
· 2008
[cited by applicant]
WO WO2008095141A2
· 2008
[cited by applicant]
WO WO2008121420A1
· 2008
[cited by applicant]
WO WO2012079000A1
· 2012
[cited by applicant]
WO WO2013019615A2
· 2013
[cited by applicant]
WO WO2014124143A1
· 2014
[cited by applicant]
WO WO2014145252A2
· 2014
[cited by applicant]
Chen, J. Gastro and Hepatology vol. 30: 1788-1795.
[cited by examiner]
Huard, 1998, Imm. Let. vol. 61: 109-112.
[cited by examiner]
Narayanan, BioRxiv, 2020, pp. 1-11.
[cited by examiner]
Rosenberg et al., “CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy,” Curr Opin Chem Eng., 19:9-20 (2018).
[cited by applicant]
Chicaybam L.: “Construção e validação de um sistema de receptores quiméricos de antígeno (CAR) ativadores e inibitórios.” Dissertação de mestrado em oncologia. Rio de Janeiro, INCA (2010) [with English abstract].
[cited by applicant]
Chicaybam et al., “Moving Receptor Redirected Adoptive Cell Therapy Toward Fine Tuning of Antitumor Responses,” Int Rev Immunol, 33:402-416 (2014).
[cited by applicant]
U.S. Appl. No. 14/851,983 (U.S. Pat. No. 11,267,901) filed Sep. 11, 2015 (Mar. 8, 2022).
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Jan. 24, 2022 Issue Fee Payment.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Oct. 25, 2021 Notice of Allowance.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Jul. 22, 2021 Response to Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Mar. 2, 2021 Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Oct. 5, 2020 Request for Continued Examination (RCE).
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Oct. 5, 2020 Response to Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed May 5, 2020 Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Mar. 30, 2020 Response to Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Oct. 28, 2019 Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Mar. 4, 2019 Request for Continued Examination (RCE).
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Mar. 4, 2019 Response to Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Dec. 17, 2018 Advisory Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Dec. 7, 2018 Response to Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Sep. 7, 2018 Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Jul. 23, 2018 Response to Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Jan. 25, 2018 Non-Final Office Action.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Nov. 26, 2017 Response to Restriction Requirement.
[cited by applicant]
U.S. Appl. No. 14/851,983, filed Jul. 18, 2018 Restriction Requirement.
[cited by applicant]
Akpek et al., “A High-Dose Pulse Steroid Regimen for Controlling Active Chronic Graft- Versus-Host Disease,” Biol. Blood Marrow Transplant. 7:495-502 (2001).
[cited by applicant]
Altvater et al., “2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells,” Clin Cancer Res 15(15):4857-4866 (2009).
[cited by applicant]
Amarnath et al., “The PDL1-PD1 Axis Converts Human THI Cells into Regulatory T Cells,” Sci. Transl. Med. 3:111ra120 (2011).
[cited by applicant]
Blattman, et al., “Cancer Immunotherapy: A Treatment for the Masses,” Science 305:200-205 (2004).
[cited by applicant]
Blazar et al., “Advances in graft-versus-host disease biology and therapy,” Nat. Rev. Immunol. 12:443-458 (2012).
[cited by applicant]
Brentjens et al., “CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia,” Sci. Transl. Med. 5:177ra38 (2013).
[cited by applicant]
Brentjens et al., “Genetically Targeted T cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts,” Clin. Cancer Res. 13(18):5426-5435 (2007).
[cited by applicant]
Brentjens et al., “Safety and persistence of adoptively transferred autologous CD 19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood 118(18):4817-4828 (2011).
[cited by applicant]
Brusko et al., “Human regulatory T cells: role in autoimmune disease and therapeutic opportunities,” Immunol. Rev. 223:371-390 (2008).
[cited by applicant]
Bryceson, “Line of attack: NK cell specificity and integration of signals,” Curr. Opin. Immunol. 20:344-352 (2008).
[cited by applicant]
Burshtyn et al., “Natural Killer Cell Conjugate Assay Using Two-Color Flow Cytometry,” Methods Mol. Biol. 612:89-96 (2010).
[cited by applicant]
Cameron et al., “Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells,” Sci. Transl. Med. 5:197ra103 (2013).
[cited by applicant]
Campoli et al., “HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance,” Oncogene 27:5869-5885 (2008).
[cited by applicant]
Casucci et al., “Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes,” Journal of Cancer, 2:378-382 (2011).
[cited by applicant]
Cartellieri et al., J. Biomed. Biotech, 1-13 (2010).
[cited by applicant]
Chaffer et al., “A Perspective on Cancer Cell Metastasis,” Science 331:1559-1564 (2011).
[cited by applicant]
Chemnitz et al., “SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death I upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation,” J. Immunol…
[cited by applicant]
Cui et al., “OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation,” PLOS One 3(8):e2990 (2008).
[cited by applicant]
Chicaybam et al., “A conditional system for the activation of lymphocytes expressing activating and inhibitory CARs,” XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), P60:1418 (2010).
[cited by applicant]
Chicaybam et al., “Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions,” International Reviews of Immunology, 30:294-311 (2011).
[cited by applicant]
Chicaybam et al., “Abstract 2797: Construction and validation of an activating and inhibitory chimeric antigen receptor (CAR) system,” Cancer Res, 74 (19_Supplement): 2797 (2014).
[cited by applicant]
Davies et al., “Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies,” Cancer Res., 70(10):3915-3924 (2010).
[cited by applicant]
Di Stasi et al., “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy,” N. Engl. J. Med. 365:1673-1683 (2011).
[cited by applicant]
Federov et al., “Inhibitory Chimeric Antigen Receptors (iCARs) Limit Undesirable Side Effects of T-Cell Therapies,” Experimental Hematology 41:S23-S75 (2013).
[cited by applicant]
Federov et al., “Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells,” The Cancer Journal 20(2):160-165 (2014).
[cited by applicant]
Federov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses,” Science Translational Medicine 5(215):215ra172 (2013).
[cited by applicant]
Ferrara et al., “Graft-versus-host disease,” Lancet 373:1550-1561 (2009).
[cited by applicant]
Francisco et al., “PD-L1 regulates the development, maintenance, and function of induced regulatory T cells,” J. Exp. Med. vol. 206: 3015-3029 (2009).
[cited by applicant]
Fu et al., “A Simple and Sensitive Method for Measuring Tumor-Specific T cell Cytotoxicity,” PLOS One 5(7):e11867 (2010).
[cited by applicant]
Gade et al., “Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes,” Cancer Res. 65(19):9080-9088 (2005).
[cited by applicant]
Hammer, “CD19 as an attractive target for antibody-based therapy,” mAbs, 571-577 (2012).
[cited by applicant]
Heider et al., “CD44v6: a target for antibody-based cancer therapy,” Canc. Immunol. Immunother. vol. 53, 567-579 (2004).
[cited by applicant]
Hodi et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” N. Engl. J. Med. 363(8):711-723 (2010).
[cited by applicant]
Hoyer et al., “CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues,” Am J Clin Pathol, 129:316-323 (2008).
[cited by applicant]
International Search Report mailed Nov. 20, 2014 in International Application No. PCT/US2014/030671.
[cited by applicant]
Kalos et al., “T cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia,” Sci. Transl. Med. 3:95ra73 (2011).
[cited by applicant]
Katchi et al., “Diagnosis and treatment of CD20 negative B cell lymphomas,” Biomak Res., vol. 5, 1-5 (2017).
[cited by applicant]
Kieback et al., “A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer,” PNAS 105(2):623-628 (2008).
[cited by applicant]
Kinoshita et al., “Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues,” World J. Surg. 30:628-636 (2006).
[cited by applicant]
Koestner et al., “PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells,” B…
[cited by applicant]
Kotsiou et al., “New ways to separate Graft-versus-Host Disease and Graft-versus-Tumour effects after allogeneic haematopoietic stem cell transplantation,” Br. J. Haematol. 160:133-145 (2013).
[cited by applicant]
Linette et al., “Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myelorna and melanoma,” Blood 122(6):863-871 (2013).
[cited by applicant]
Lupo-Stanghellini et al., “Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation,” Hum. Gene Ther. 21:241-250 (2010).
[cited by applicant]
Maher et al., “Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor,” Nat. Biotechnol. 20:70-75 (2002).
[cited by applicant]
Markley et al., “IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immuno-deficient mice,” Blood 115(17):3508-3519 (2010).
[cited by applicant]
Meimei et al., “Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells,” Med. Oncol 28:282-289 (2011).
[cited by applicant]
Morgan et al., “Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy,” J. Immunother. 36(2):133-151 (2013).
[cited by applicant]
Morgan et al., “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2,” Mol. Ther. 18(4):843-851 (2010).
[cited by applicant]
Nakase et al., “Myeloid Antigen, CD13, CD14, and/or CD33 Expression Is Restricted to Certain Lymphoid Neoplasms,” Am J. Path. vol. 105, 761-768, (1996).
[cited by applicant]
Nishimura et al., “Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif Carrying Immunoreceptor,” Immunity 11:141-151 (1999).
[cited by applicant]
Padmanee et al., “Novel cancer immunotherapy agents with survival benefit: recent successes and next steps,” Nature Reviews Cancer 11(11):805-812 (2011).
[cited by applicant]
Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nat. Rev. Cancer 12:252-264 (2012).
[cited by applicant]
Parry et al., “CTLA-4 and PD-1 Receptors Inhibit T-cell Activation by Distinct Mechanisms,” Mol. Cell. Biol. 25(21):9543-9553 (2005).
[cited by applicant]
Pedicord et al., “Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance,” PNAS 108:266-271 (2011).
[cited by applicant]
Peggs et al., “Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy,” Immunol. Rev. 224:141-165 (2008).
[cited by applicant]
Restifo et al., “Adoptive immunotherapy for cancer: Harnessing the T cell response,” Nat. Rev. Immunol. 12:269-281 (2012).
[cited by applicant]
Rudd, “The reverse stop-signal model for CTLA4 function,” Nat. Rev. Immunol. 8:153-160 (2008).
[cited by applicant]
Sadelain et al., “The Basic Principles of Chimeric Antigen Receptor Design,” Cancer Discov. 3(4):388-398 (2013).
[cited by applicant]
Sadelain et al., “The promise and potential pitfalls of chimeric antigen receptors,” Curr. Opin. Immunol. 21:215-223 (2009).
[cited by applicant]
Sharma et al., “Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps,” Nat. Rev. Cancer 11:805-812 (2011).
[cited by applicant]
Silver et al., “Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues,” Clin. Cancer Res., 3:81-85 (1997).
[cited by applicant]
Singh et al., “p53 Target Gene SMAR1 is Dysregulated in Breast Cancer: Its Role in Cancer Cell Migration and Invasion,” PLOS One 2(8):e660 (2007).
[cited by applicant]
Stephan et al., “T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection,” Nat. Med. 13(12):1440-1449 (2007).
[cited by applicant]
Teft et al., “A Molecular Perspective of CTLA-4 Function,” Annu. Rev. Immunol. 24:65-97 (2006).
[cited by applicant]
Thaventhiran et al., “T Cell Co-inhibitory Receptors: Functions and Signalling Mechanisms,” J Clin Cell Immunol s12:1-12 (2012).
[cited by applicant]
Themeli et al., “Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy,” Nat. Biotechnol. 31(10):928-933 (2013).
[cited by applicant]
Tivol et al., “Loss of CTLA-4 leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4,” Immunity 3:541-547 (1995).
[cited by applicant]
Topalian et al., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” N. Engl. J. Med. 366(26):2443-2454 (2012).
[cited by applicant]
Torikai et al., “A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR,” Blood, 119(24):5697-5705 (2012…
[cited by applicant]
Tsuboi et al., “Two opposing roles of O-glycans in tumor metastasis,” Trends Mol. Med. 18(4):224-232 (2012).
[cited by applicant]
Tsuchiya et al., “Differential expression of N-cadherin and E-cadherin in normal human tissues,” Arch. Histol. Cytol.69(2):135-145 (2006).
[cited by applicant]
Turtle et al., “Engineered T cells for anti-cancer therapy,” Curr. Opin. Immunol. 24:633-639 (2012).
[cited by applicant]
Uhlen et al., “Towards a knowledge-based Human Protein Atlas,” Nat. Biotechnol. 28(12):1248-1250 (2010).
[cited by applicant]
Velu et al., “Enhancing SIV-specific immunity in vivo by PD-I blockade,” Nature 458:206-210 (2009).
[cited by applicant]
Vogler et al., “An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T cells for Adoptive Immunotherapy,” Mol. Ther. 18(7):1330-1338 (2010).
[cited by applicant]
Wang et al., “Establishment of NOD-Pdcdl-/- mice as an efficient animal model of type I diabetes,” PNAS 102(33):11823-11828 (2005).
[cited by applicant]
Wilkie et al., “Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling,” Journal of Clinical Immunology 32(5):1059-1070 (2012).
[cited by applicant]
Yazawa et al., “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease,” PNAS 102(42):15178-15183 (2005).
[cited by applicant]
Yokosuka et al., “Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2,” J. Exp. Med. 209(6):1201-1217 (2012).
[cited by applicant]
Yuan et al., “Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen Specific CD8+ Cytolytic T Lymphocyte Respons…
[cited by applicant]